Prof. Fengyong Liu 刘凤永
Chief Physician, Professor
Department of Interventional Radiology, Chinese PLA General Hospital (301 Hospital), First Medical Center, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Interventional radiology for malignant and benign tumors, vascular diseases, and stenosis. Techniques include TACE, radiofrequency ablation, irreversible electroporation (Nanoknife), cryoablation, and radioactive seed implantation. Performs biopsies and emergency hemostasis.
Dr. Liu is a Chief Physician and Professor at the First Medical Center of Chinese PLA General Hospital. Dr. Liu was a senior visiting scholar at MD Anderson Cancer Center (2013–2014) and a postdoctoral fellow at Massachusetts General Hospital, Harvard University (2014–2016). Dr. Liu conducts clinical and basic research on interventional treatment for tumors and vascular diseases.
Professional roles
- Vice Chair and Secretary-General, Interventional Diagnosis and Treatment Branch, China International Exchange and Promotion Association for Medical and Healthcare
- Vice Chair, Molecular Diagnostic Medicine Professional Committee, Chinese Research Hospital Association
- Standing Committee Member, Tumor Minimally Invasive Intervention Professional Committee, Chinese Research Hospital Association
- Member, Contrast Agent Group, Chinese Society of Radiology
Name order: in Chinese the family name comes first (Liu Fengyong). Papers usually list the name as Fengyong Liu or Liu F.
Selected publications
65 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- ILIVER, 2025 (senior author): Practice revolution in local interventional therapy for liver metastases. PubMed 40636462
- Abdom Radiol (NY), 2024 (senior author): Targeted redox-responsive peptide for arterial chemoembolization therapy of orthotropic hepatocellular carcinoma. PubMed 38990300
- Chin Med J (Engl), 2024 (senior author): REBOA: A novel life-saving tool for non-compressible traumatic hemorrhage. PubMed 39101488
- Mil Med Res, 2023 (senior author): Pre-hospital application of REBOA for life-threatening hemorrhage. PubMed 38087389
- J Clin Transl Hepatol, 2023 (first author): MRI/PAI Dual-modal Imaging-guided Precise Tracking of Bone Marrow-derived Mesenchymal Stem Cells Labeled with Nanoparticles for Treating Liver Cirrhosis. PubMed 36643042
- Abdom Radiol (NY), 2020 (senior author): Comparison of Angio-CT and cone-beam CT-guided immediate radiofrequency ablation after transcatheter arterial chemoembolization for large hepatocellular carcinoma. PubMed 32107583
- Ann Transl Med, 2019 (first author): A new management strategy for renal angiomyolipomas: superselective arterial embolization in combination with radiofrequency ablation. PubMed 32042782
- Cancer Imaging, 2019 (senior author): Local application of doxorubicin- loaded Iron oxid nanoparticles and the vascular disrupting agent via the hepatic artery: chemoembolization-photothermal ablation treatment of hepatocellular carcinoma in rats. PubMed 31685015
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion